Recent

% | $
Quotes you view appear here for quick access.

Novartis AG Message Board

  • bluecheese4u bluecheese4u Oct 25, 2012 1:58 AM Flag

    Novartis Third quarter 2012 results

    Novartis Third quarter 2012 results

    Recently launched products support Novartis sales in third quarter, offsetting
    patent expiry; Pharmaceuticals well-positioned with further pipeline progress
     Group net sales declined 2% in constant currencies (cc) in the third quarter, down 1% over
    nine months
    o Third quarter net sales reached USD 13.8 billion (-7%, -2% cc); nine months net sales were USD
    41.8 billion (-4%, -1% cc)
    o Core1 operating income was USD 3.9 billion (-5%, -3% cc) in third quarter, USD 11.5 billion
    (-7%, -4% cc) in nine months; operating income reached USD 3.0 billion (+3%, +5% cc) in the
    third quarter and USD 9.0 billion (-7%, -4% cc) for the nine months
    o Core EPS was USD 1.34 (-8%, -6% cc) in third quarter, USD 3.98 (-8%, -5% cc) in nine months;
    EPS was USD 1.01 (-1%, +2% cc) in third quarter and USD 3.09 (-7%, -4% cc) in nine months
    o Free cash flow1 reached USD 3.5 billion for third quarter (2011 USD 3.7 billion); USD 7.9 billion
    in nine months (2011 USD 8.6 billion)
     Strong flow of innovation news continues; respiratory portfolio prospects significantly
    advanced with QVA149 EU filing
    o Eight regulatory milestones in Pharmaceuticals, including Afinitor FDA and EMA approval in
    advanced breast cancer, Jakavi EMA approval in myelofibrosis and Seebri Breezhaler EMA
    approval in COPD
    o Respiratory portfolio progressed with strong Phase III trials of QVA149 leading to filing in the EU
     Recently launched products in Pharmaceuticals totaled USD 2.8 billion and represented 36%
    of net sales (USD 8.3 billion and 35% of net sales for nine months); Pharmaceuticals wellpositioned
    to emerge from Diovan patent expiry
     Quality remediation continues to be actively addressed; first Consumer Health products
    resupplied in the US from third party sources
     2012 Group performance outlook reaffirmed
    Key figures

    novartis

    Novartis Q3 and 9M 2012 Interim Financial Report – Supplementary Data

    novartis

    URLs at talkstock

 
NVS
99.72+1.11(+1.13%)2:52 PMEDT